Evotec SE, DE0005664809

Evotec stock costs EUR 2.56 as Evotec reports preliminary results

Published on 10/18/2026 at 17:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock costs EUR 2.56 in weekend trading on October 18, 2026 versus Xetra's EUR 2.57 close. Evotec expects EUR 465.00 million revenue.

Results and session dates

  • Evotec announced preliminary nine-month results on October 13, 2026.
  • Evotec stock trades in weekend trading at Lang & Schwarz at EUR 2.56 at 5:00 p.m. CEST on October 18, 2026, 0.39 percent below the Xetra close of October 16, 2026.
  • Full third-quarter and nine-month results are scheduled for November 5, 2026.
Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock costs EUR 2.56 in weekend trading at Lang & Schwarz at 5:00 p.m. CEST on October 18, 2026, 0.39 percent below the Xetra close of EUR 2.57 on October 16, 2026.

Weekend trading

The euro price is based on the Lang & Schwarz quote for Evotec SE. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CEST is shown by the continuously updated real-time quote of Evotec stock.

Preliminary nine-month results

In an EQS News release dated October 13, 2026, Evotec reported preliminary unaudited results for the first nine months of 2026. The company expects revenue of EUR 465.00 million and adjusted EBITDA of negative EUR 42.80 million for that period. Evotec reaffirmed its full-year 2026 guidance, including revenue of EUR 570.00 million to EUR 610.00 million and adjusted EBITDA of negative EUR 70.00 million to negative EUR 105.00 million.

Next reporting date

Evotec said the full financial results for the third quarter and the first nine months of 2026 are scheduled for publication on November 5, 2026.

Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70353990 | bgmi